Literature DB >> 21561937

Meta-analysis of second cancer risk after radiotherapy among childhood cancer survivors.

Kazutaka Doi1, Makiko N Mieno, Yoshiya Shimada, Hidenori Yonehara, Shinji Yoshinaga.   

Abstract

Cancer risks among childhood cancer survivors following radiotherapy have not yet been well characterised in terms of radiation dose. A meta-analysis of studies on the excess relative risk per gray (ERR) of second cancer was conducted previously; unfortunately, the small number of eligible studies restricted quantitative evaluations. To solve this problem, a statistical method to calculate ERR estimates from other estimates was developed, and a meta-analysis was conducted again. The PubMed database was searched and 26 relevant studies were identified. ERR estimates were available in 15 studies, and for the other 11 studies, the regression-based model was used to calculate ERR estimates from other estimates. The overall ERR estimate was 0.40, which was much lower than that of atomic bomb survivors exposed as young children. Heterogeneity of the risk among studies was suggested, and a further study is needed to explore the heterogeneity among studies.

Entities:  

Mesh:

Year:  2011        PMID: 21561937     DOI: 10.1093/rpd/ncr166

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  6 in total

1.  Local radiation dose and solid second malignant neoplasms after childhood cancer in Germany: a nested case-control study.

Authors:  Ulrike Hennewig; Peter Kaatsch; Maria Blettner; Claudia Spix
Journal:  Radiat Environ Biophys       Date:  2014-05-27       Impact factor: 1.925

Review 2.  Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship.

Authors:  Amy Berrington de Gonzalez; Ethel Gilbert; Rochelle Curtis; Peter Inskip; Ruth Kleinerman; Lindsay Morton; Preetha Rajaraman; Mark P Little
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-24       Impact factor: 7.038

Review 3.  Emerging targets for radioprotection and radiosensitization in radiotherapy.

Authors:  Sumit Kumar; Rajnish Kumar Singh; Ramovatar Meena
Journal:  Tumour Biol       Date:  2016-06-19

4.  Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.

Authors:  M B Miranda; M Lauseker; M-P Kraus; U Proetel; B Hanfstein; A Fabarius; G M Baerlocher; D Heim; D K Hossfeld; H-J Kolb; S W Krause; C Nerl; T H Brümmendorf; W Verbeek; A A Fauser; O Prümmer; K Neben; U Hess; R Mahlberg; C Plöger; M Flasshove; B Rendenbach; W-K Hofmann; M C Müller; M Pfirrmann; A Hochhaus; J Hasford; R Hehlmann; S Saußele
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

Review 5.  Evolving Clinical Cancer Radiotherapy: Concerns Regarding Normal Tissue Protection and Quality Assurance.

Authors:  Won Hoon Choi; Jaeho Cho
Journal:  J Korean Med Sci       Date:  2016-01-28       Impact factor: 2.153

6.  Methodological extensions of meta-analysis with excess relative risk estimates: application to risk of second malignant neoplasms among childhood cancer survivors treated with radiotherapy.

Authors:  Kazutaka Doi; Makiko N Mieno; Yoshiya Shimada; Hidenori Yonehara; Shinji Yoshinaga
Journal:  J Radiat Res       Date:  2014-07-18       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.